Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, Mass. and SOMERSET, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced...
-
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has named Gad Berdugo as the Company’s Chief...
-
CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
-
CAMBRIDGE, Mass., and WALTHAM, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group...
-
CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten...
-
CAMBRIDGE, Mass., June 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000...
-
CAMBRIDGE, Mass., June 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of its...
-
CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study of...
-
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene...
-
Patient dosing initiated in BRILLIANCE Phase 1/2 trial of EDIT-101 (AGN-151587) for LCA10 On track to file IND for EDIT-301 for sickle cell disease by end of 2020 Initiated IND-enabling studies for...